Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05395403 · ClinicalTrials.gov registry record · NA

Use of Automated Office Blood Pressure Monitoring

A NA study, sponsored by University of Alabama at Birmingham.

Completed
Registry status
NA
Development phase
28
Enrollment target

NCT05395403: Completed NA study, sponsored by University of Alabama at Birmingham.

NCT05395403 is a NA study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 28 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05395403, a NA study, has completed, sponsored by University of Alabama at Birmingham.

COMPLETED
Registry status
NA
Development phase
28 participants
Enrollment target

Study Summary

Blood pressure measurements by three methods Office Blood Pressure Measurement (OBPM), Automated Office Blood Pressure Measurement (AOBPM), and Home Blood Pressure Measurement (HBPM) were collected retrospectively across three visits for patients (N=28) referred to a specialty hypertension (HTN) clinic. Demographic data were analyzed using summary statistics. The differences between AOBPM, HBPM, and OBPM were examined using mixed models repeated measures analysis for time and method for each visit.

Primary Outcome

Blood pressure control: Traditional office blood pressure measurement less than 140/90 mm Hg

Interventions

  • DEVICE Blood pressure measurement device

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2021-03-05
Est. Completion 2021-07-05
Phase NA
University of Alabama at Birmingham

1,160 total trials

What the finished NCT05395403 record still lists

NCT05395403 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 1 intervention - of which Blood pressure measurement device is the first listed.

NCT05395403 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05395403 about?

NCT05395403 is a clinical study titled "Use of Automated Office Blood Pressure Monitoring". Blood pressure measurements by three methods Office Blood Pressure Measurement (OBPM), Automated Office Blood Pressure Measurement (AOBPM), and Home Blood Pressure Measurement (HBPM) were collected retrospectively across three visits for patients (N=28) referred to a specialty hypertension (HTN) cli...

What is the current status of trial NCT05395403?

This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2021-03-05. Estimated completion is 2021-07-05.

What interventions are being tested in trial NCT05395403?

The interventions under investigation include: Blood pressure measurement device (DEVICE).

Who is sponsoring clinical trial NCT05395403?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05395403's enrollment target sits among peer trials

28 1704th of 2000 higher than 293 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03471117 · 28 participants · Phase 4

    Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

  • NCT03523975 · 28 participants · Phase 1

    Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

  • NCT03608631 · 28 participants · Phase 1

    iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

  • NCT03810651 · 28 participants · Early Phase 1

    Pencil Beam Scanning in Patients With Renal Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05395403, the US trial registry maintained by the National Library of Medicine. NCT05395403 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.